22157.jpg
Global Gastrointestinal Partnering Report and Directory 2022: Trends by Year, Deal Type, Stage of Development, Technology Type and Therapeutic Indication
December 02, 2022 08:09 ET | Research and Markets
Dublin, Dec. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Gastrointestinal Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The...
Global Inflammatory Bowel Disease Treatment Market Research Report 2022 Featuring AbbVie, Biogen, Johnson & Johnson, Amgen, & UCB SA
November 08, 2022 06:13 ET | Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global inflammatory...
Capture_brand and logo.PNG
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022
November 02, 2022 08:00 ET | Morphic Therapeutic
Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule EMERALD-2 phase 2b global randomized study of MORF-057 to begin fourth quarter ...
Capture_brand and logo.PNG
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
October 25, 2022 16:05 ET | Morphic Therapeutic
Saturating receptor occupancy at 100 and 200 mg BID doses Statistically significant effects on key lymphocyte subsets WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq:...
Capture_brand and logo.PNG
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
October 24, 2022 08:00 ET | Morphic Therapeutic
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
October 10, 2022 08:00 ET | Morphic Therapeutic
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor ...
AMR Logo.png
Global Inflammatory Bowel Disease Treatment Market Is Expected to Reach $34.5 Billion by 2031: Allied Market Research
September 08, 2022 08:59 ET | Allied Market Research
Portland, OR, Sept. 08, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Inflammatory Bowel Disease Treatment Market generated $21.0 billion in 2021,...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
August 29, 2022 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma, Inc. Announces Reverse Stock Split
August 25, 2022 12:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
TIP_link_300x300.jpg
Colorectal Procedure Market to Garner $29.55Bn, Globally, by 2028 Growing at 13.1% CAGR | Exclusive Report by The Insight Partners
August 24, 2022 05:16 ET | The Insight Partners
New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Colorectal Procedure Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product,...